Sarepta Therapeutics just delivered one of the most dramatic earnings beats in its recent history — and yet the short position barely flinched.
Q1 adjusted EPS of $3.16 demolished the $0.99 consensus estimate by more than 200%. Revenue of $730.8 million shredded the $474.2 million forecast. ELEVIDYS, the company's gene therapy for Duchenne muscular dystrophy, is clearly performing well ahead of even the most optimistic Street projections. The stock has reclaimed 3.4% over the past week heading into the print, but it remains down 6.2% over the past month and trades at just $21.79 — a price that sits well below even the most bearish analyst targets, which tells its own story about how far the stock has fallen and how hard it is to rebuild confidence after a contentious regulatory chapter.
The short position is enormous and remarkably sticky. Short interest in SRPT runs at 26.9% of the free float — roughly one share in four is borrowed and sold. That level has barely moved in months, oscillating in a narrow 25–27% band since late March. The one-month change is a modest 4.5% increase in shares short. This is not a position that is capitulating into a blowout earnings beat. For context, official FINRA data from the April 15 settlement puts short shares at 25.3 million with days-to-cover of 11.5 — meaning it would take nearly two and a half trading weeks to unwind the position at average volume. That is an unusually large overhang for any stock, let alone one that just printed a triple-digit EPS beat.
Borrow conditions offer little signal of forced covering ahead. Cost to borrow remains cheap at 0.43%, up 17% over the past month but in absolute terms still near rock bottom for a name this heavily shorted. Availability has eased recently — borrow pool utilization has dropped from 14–15% in early April to around 10.5% now, meaning shares to lend remain plentiful relative to what is already borrowed. The ORTEX short score of 63.6 has been stable all week, with almost no directional drift. Options traders are slightly more defensive than usual: the put/call ratio hit 0.80 on Tuesday, nearly two standard deviations above its 20-day average of 0.75. It is not an extreme reading, but the direction of travel — PCR creeping higher as earnings approached — adds a layer of caution.
The Street's split on SRPT is pronounced. Eight analysts carry buy ratings against twelve holds, with zero sells from the major houses — though HC Wainwright and Citigroup both maintain sell calls with targets of $5 and $13 respectively. Those numbers look deeply inconsistent with a stock trading at $21.79 on the back of a quarter this strong, and readers should treat those targets as reflecting the EMBARK trial overhang rather than any current commercial reality. On the bull side, Oppenheimer holds at $37, Mizuho lifted its target to $31 in March, and Wells Fargo, despite trimming from $45 to $38 after Q4, still sees meaningful upside. Valuation multiples have compressed: the EV/EBITDA of 7.2x has expanded roughly 0.8x over thirty days, while the P/E ratio runs at 5.96x — strikingly cheap if ELEVIDYS adoption continues at Q1's pace. The EPS surprise factor score sits at the 96th percentile of the universe; the analyst recommendation divergence score ranks at the 97th. That combination — beats running near the top of the market while the Street consensus remains cautious — defines the core tension here.
The bear case, however, is not trivial. Short sellers have sat through months of negative price action and are clearly not deterred by one quarter. The EMBARK trial failure and the ongoing questions about ELEVIDYS's secondary endpoints remain unresolved. The company's own posted equity value of roughly $618 million on a discounted cash flow basis, cited in the bear analysis, clashes sharply with the commercial momentum now visible in the Q1 numbers — and that dispute is likely to define the next several months of debate. The next earnings event is scheduled for June 4, giving the market less than a month to re-price the stock in light of today's results.
With a short base this entrenched facing a revenue beat of this magnitude, the next few sessions will test whether bears treat Q1 as a one-off or begin a genuine re-evaluation of ELEVIDYS's trajectory.
See the live data behind this article on ORTEX.
Open SRPT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
